Clinical characteristics of heart disease patients with a good prognosis in spite of markedly increased plasma levels of type-B natriuretic peptide (BNP): Anomalous behavior of plasma BNP in hypertrophic cardiomyopathy

Circulation Journal

Volumn 69, Issue 3, 2005, Pages 277-282

  Takeuchi, Ichiro ^a   Inomata, Takayuki ^a   Nishii, Mototsugu ^a   Koitabashi, Toshimi ^a   Nakano, Hironari ^a   Shinagawa, Hisahito ^a   Takehana, Hitoshi ^a   Izumi, Tohru ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Heart failure; Hypertrophic cardiomyopathies; Natriuretic peptides; Prognosis

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; NORADRENALIN; RENIN;

AGED; ARTICLE; ECHOCARDIOGRAPHY; FEMALE; HEART DISEASE; HEART FAILURE; HUMAN; HUMAN CELL; HYPERTROPHIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; NORADRENALIN BLOOD LEVEL; OUTPATIENT; PARAMETER; PLASMA RENIN ACTIVITY; PROGNOSIS;

AGED; BIOLOGICAL MARKERS; CARDIOMYOPATHY, HYPERTROPHIC; ELECTROCARDIOGRAPHY; FEMALE; HEART DISEASES; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NOREPINEPHRINE; PROGNOSIS; RENIN; SEVERITY OF ILLNESS INDEX;

EID: 15744387563     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.69.277     Document Type: Article

References (39)

1. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87: 1402-1412.
2. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96: 509-516.
3. Berger R, Huelsman M, Strecker K, Bojic A, Maser P, Stanek B, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002; 105: 2392-2397.
4. Koseki Y, Watanabe J, Shinozaki T, Sakuma M, Komaru T, Fukuchi M, et al. Characteristics and 1-year prognosis of medically treated patients with chronic heart failure in Japan-chronic heart failure analysis registry in Tohoku district (CHART). Circ J 2003; 67: 431-436.
5. McCullough PA, Nowak RM, McCord J, Hollander JE, Hermann HC, Steg PG, et al. B-type natriuretic peptide and clinical judgement in emergency diagnosis of heart failure: Analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 2002; 106: 416-422.
6. Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 2002; 39: 202-209.
7. Nagao K, Hayashi N, Kanmatsuse K, Kikuchi S, Kikushima K, Watanabe K, et al. B-type natriuretic peptide as a marker of resuscitation in patients with cardiac arrest outside the hospital. Circ J 2004; 68: 477-482.
8. Troughton RW, Fampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma amino-terminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: 1126-1139.
9. Inomata T, Nishii M, Takehana H, Takeuchi I, Koitabashi T, Nakano H, et al. Brain natriuretic peptide-guided treatment reduces cardiovascular events of heart failure in outpatient management (abstract). Circulation 2002; 106: 416.
10. Turner AF. The chest radiograph: A systematic approach to interpretation for the internist. Curr Probl Cardiol 1978; 3: 1-50.
11. Briguori C, Betocchi S, Losi MA, Manganelli F, Pace L, Boccalatte M, et al. Noninvasive evaluation of left ventricular diastolic function in hypertrophic cardiomyopathy. Am J Cardiol 1998; 81: 180-187.
12. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol 1986; 57: 450-458.
13. Schiller NB, Acquatella H, Ports TA, Drew D, Goerke J, Ringertz H, et al. Left ventricular volume from paired biplane two-dimensional echocardiography. Circulation 1979; 60: 547-555.
14. WHO/ISFC Task Force. Report of the WHO/ISFC Task Force on the Definition and Classification of Cardiomyopathies. Br Heart J 1980; 44: 672-673.
15. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311: 819-823.
16. Charles CJ, Espiner EA, Nicholls MG, Richards AM, Yandle TG, Protter A, et al. Clearance receptors and endopeptidase: Equal role in natriuretic peptide metabolism in conscious sheep. Am J Physiol 1996; 271: 373-380.
17. Nomura H, Hayashi T, Esaki T, Kanda S, Kano H, Hattori A, et al. Standardization of plasma brain natriuretic peptide concentrations in older Japanese-relationship to latent renal dysfunction and ischemic heart disease. J Am Geriatr Soc 2002; 50: 1504-1509.
18. McCullough PA, Due P, Omland T, McCord J, Nowak RM, Hollander JE, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: An analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003; 41: 571-579.
19. Redfield MM, Rodehefer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC. Plasma brain natriuretic peptide concentration: Impact of age and gender. J Am Coll Cardiol 2002; 40: 976-982.
20. Kikuchi M, Inagaki T. Atrial natriuretic peptide in aged patients with iron deficiency anemia. Arch Gerontol Geriatr 1999; 28: 105-115.
21. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998; 135: 825-832.
22. Ishida Y, Meisner JS, Tsujioka K, Gallo JI, Yoran C, Frater RW, et al. Left ventricular filling dynamics: Influence of left ventricular relaxation and left atrial pressure. Circulation 1986; 74: 187-196.
23. Braunwald E, Frahm CJ. Studies on Starling's law of the heart, IV: Observations on the hemodynamic functions of the left atrium in man. Circulation 1961; 24: 633-642.
24. Bruneau BG. Transcriptional regulation of vertebrate cardiac morphogenesis. Circ Res 2002; 90: 509-519.
25. Ogino K, Ogura K, Kinugawa T, Osaki S, Kato M, Furuse Y, et al. Neurohumoral profiles in patients with hypertrophic cardiomyopathy-differences to hypertensive left ventricular hypertrophy. Circ J 2004; 68: 444-450.
26. Kohno M, Horio T, Yokokawa K, Murakawa K, Yasunari K, Akioka K, et al. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med 1992; 92: 29-34.
27. Hasegawa K, Fujiwara H, Doyama K, Miyatake M, Fujiwara T, Suga S, et al. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circulation 1993; 88: 372-380.
28. Nishigaki K, Tomita M, Kagawa K, Noda T, Minatoguchi S, Oda H, et al. Marked expression of plasma brain natriuretic peptide is a special feature of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1996; 28: 1234-1242.
29. Briguori C, Betocchi S, Manganelli F, Gigante B, Losi MA, Ciampi Q, et al. Determinants and clinical significance of natriuretic peptides and hypertrophic cardiomyopathy. Eur Heart J 2001; 22: 1328-1336.
30. Franz WM, Muller OJ, Katus HA. Cardiomyopathies: From genetics to the prospect of treatment. Lancet 2001; 358: 1627-1637.
31. Lankford EB, Epstein ND, Fananapazir L, Sweeney HL. Abnormal contractile properties of muscle fibers expressing beta-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathy. J Clin Invest 1995; 95: 1409-1415.
32. Elliott K, Watkins H, Redwood CS. Altered regulatory properties of human cardiac troponin I mutants that cause hypertrophic cardiomyopathy. J Biol Chem 2000; 275: 22069-22074.
33. Sanbe A, Nelson D, Gulick J, Setser E, Osinska H, Wang X, et al. In vivo analysis of an essential myosin light chain mutation linked to familial hypertrophic cardiomyopathy. Circ Res 2000; 87: 296-302.
34. Paulus WJ. Natriuretic peptides to probe haemodynamic overload in hypertrophic cardiomyopathy. Eur Heart J 2001; 22: 1249-1251.
35. Nakamura T, Sakamoto K, Yamano T, Kikkawa M, Zen K, Hikosaka T, et al. Increased plasma brain natriuretic peptide level as a guide for silent myocardial ischemia in patients with non-obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 39: 1657-1663.
36. Yoshimura M, Yasue H, Morita E, Sakaino N, Jougasaki M, Kurose M, et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 1991; 84: 1581-1588.
37. Latini R, Masson S, Anand I, Salio M, Hester A, Judd D, et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004; 25: 292-299.
38. Francis GS, Benedict C, Johnston DE, Kirlin PC, Nkcklas J, Liang CS, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82: 1724-1729.
39. Paganelli WC, Creager MA, Dzau VJ. Cardiac regulation of renal function. In: Cheng TO, editor. International Textbook of Cardiology. New York: Pergammon Press; 1986; 1010-1020.